Switch to:
More From Other Websites
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : April 27, 2017 Apr 27 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US :... Apr 26 2017
Ligand to Report First Quarter 2017 Results on May 9th Apr 13 2017
3 Stocks With Apple-Like Return Potential Apr 11 2017
Ligand Enters Commercial License and Supply Agreements with Marinus Pharmaceuticals for... Apr 05 2017
Ligand Announces Licensing Partner Janssen Has Filed an IND for an Antibody Discovered Using the... Mar 28 2017
3 Least Risky Biotech Stocks on the Market Mar 28 2017
3 Stocks to Invest in Healthcare Mar 26 2017
Ligand to Participate in Upcoming Investor Conference Mar 09 2017
New Strong Sell Stocks for March 7th Mar 07 2017
Ligand Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LGND-US :... Mar 07 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: 2016 By the Numbers : March 1, 2017 Mar 01 2017
Ligand Provides Highlights from Today’s Analyst Day Event Feb 28 2017
Ligand Expands License with Sermonix to Include Worldwide Rights for Oral Lasofoxifene Feb 28 2017
6 Stocks on the Move With Unusual Volume Feb 28 2017
Sermonix Pharmaceuticals Secures Worldwide Rights to Oral Lasofoxifene From Ligand Pharmaceuticals,... Feb 28 2017
Ligand Pharmaceuticals, Inc. :LGND-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27,... Feb 27 2017
Enrollment Completed in Ligand’s Phase 2 Trial of LGD-6972 in Type 2 Diabetes Feb 27 2017
Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates Feb 24 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK